These findings suggest a potential protective effect of H1 and H2 receptor antagonists, concluding that antihistamine compounds or histidine decarboxylase inhibitors may be used to inhibit osteoclastic activity and bone resorption in secondary osteoporosis related to systemic mastocytosis [23]. The gene discussed is HDC; the disease is osteoporosis.